Article Details
Retrieved on: 2024-10-07 20:44:45
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses a biopharma initiative to enhance cancer immunotherapy effectiveness using MB097, a precision microbiome therapy. It targets immune checkpoint inhibitors, like pembrolizumab, particularly for melanoma patients resistant to existing treatments, integrating immune system knowledge, PD-1 inhibitors, and natural killer cell activation.
Article found on: www.scientistlive.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here